Waters Corporation
WAT Healthcare Diagnostics & Research
Waters Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 6.99% from fiscal 2024. In the quarter to June 2026, revenue grew 113.4%, EPS fell 156.3%, free cash flow grew 750.0% and total debt rose 308.2%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow WAT
Waters Corporation (WAT) EPS (diluted)
Waters Corporation's EPS (diluted) for fiscal 2025 was $10.76, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $4.01. Over the past ten years it has ranged from $0.25 (fiscal 2017) to $11.73 (fiscal 2022); the current reading is higher than 73% of that period. Waters Corporation ranks 13th of 52 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $10.76 | 0.47% |
| FY2024 | $10.71 | (1.20%) |
| FY2023 | $10.84 | (7.59%) |
| FY2022 | $11.73 | 5.01% |
| FY2021 | $11.17 | 33.61% |
| FY2020 | $8.36 | (3.80%) |
| FY2019 | $8.69 | 13.59% |
| FY2018 | $7.65 | 2,960.00% |
| FY2017 | $0.25 | (96.10%) |
| FY2016 | $6.41 | 13.45% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$1.39 | — |
| Mar 2026 | −$0.87 | — |
| Dec 2025 | $3.77 | 50.80% |
| Sep 2025 | $2.50 | 1.21% |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| MTD Mettler-Toledo International, Inc. compare | $44.43 |
| IDXX IDEXX Laboratories, Inc. compare | $14.22 |
| LH Labcorp Holdings Inc. compare | $12.09 |
| DGX Quest Diagnostics Incorporated compare | $9.42 |
| IQV IQVIA Holdings Inc. compare | $8.06 |
| ILMN Illumina, Inc. compare | $5.36 |
| A Agilent Technologies, Inc. compare | $5.08 |
| WAT Waters Corporation | $4.01 |
| NTRA Natera, Inc. compare | −$1.36 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on WAT
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement